Rosen Law Firm Reminds Investors of Lead Plaintiff Deadline in Pacira BioSciences, Inc. Securities Class Action
NEW YORK, Feb. 17, 2025 /PRNewswire/ —
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the “Class Period”), of the important March 14, 2025 lead plaintiff deadline.
So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Investors are reminded that in order to be eligible for potential compensation, they must meet the lead plaintiff requirements, which include filing a lead plaintiff motion by the deadline mentioned above.
The securities class action lawsuit alleges that Pacira BioSciences made false and/or misleading statements and/or failed to disclose that the company’s flagship product was facing intense competition from other pharmaceutical companies, which was negatively impacting its sales and revenue.
Pacira BioSciences investors are encouraged to contact the Rosen Law Firm to discuss their legal rights and potential options for seeking compensation through the securities class action lawsuit.
Don’t miss the deadline – take action today to protect your investment and potential recovery.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
Email: [email protected]
[email protected]
[email protected]
Web: www.rosenlegal.com
How this will affect me:
If you are a purchaser of Pacira BioSciences securities during the Class Period, you may be entitled to compensation through the securities class action lawsuit. By taking action and filing a lead plaintiff motion by the deadline, you may be able to recover losses incurred as a result of alleged false or misleading statements made by the company.
How this will affect the world:
The outcome of the securities class action lawsuit against Pacira BioSciences could have broader implications for the pharmaceutical industry as a whole. Companies may be held accountable for making false or misleading statements that impact investors and market stability. This case could set a precedent for increased transparency and accountability in the industry.
Conclusion:
It is vital for investors who purchased Pacira BioSciences securities during the Class Period to take action before the lead plaintiff deadline on March 14, 2025. By seeking compensation through the securities class action lawsuit, you can protect your investment and potentially recover losses. Contact the Rosen Law Firm today to discuss your legal rights and options.
